In a clinical trial, men with newly diagnosed, metastatic, hormone-sensitive prostate cancer who received chemotherapy straight away alongside hormone-blocking therapy lived more than a year longer than men who followed the standard treatment – which is to wait until the tumours have become resistant to hormone therapy before receiving chemotherapy. [s]Medical News Today[/s] reports that the scientists running the [b]National Cancer Institute[/b]-funded phase-3 trial are from the [b]Dana-Farber Cancer Institute[/b] and the [b]Eastern Co-operative Oncology Group[/b]. They say the dramatic results are likely to change current standard practice, which has been routine since the 1950s.
[link url=http://www.medicalnewstoday.com/articles/277621.php]Full Medical News Today report[/link]
[link url=http://abstracts.asco.org/144/AbstView_144_127755.html]ASCO abstract[/link]